## Management of Benign Genital HPV Infection **Key Point:** HPV-6 and HPV-11 are low-risk (non-oncogenic) types that cause benign condyloma acuminata. The goal of treatment is symptomatic relief and lesion clearance, not cancer prevention. ### Treatment Options for Genital Warts | Treatment | Indication | Mechanism | Success Rate | |-----------|-----------|-----------|---------------| | Topical imiquimod | First-line for small, accessible lesions | TLR7 agonist; stimulates local immune response | 50–90% | | Podophyllin/Podofilox | Accessible lesions; patient-applied | Cytotoxic; arrests metaphase | 40–70% | | Cryotherapy | Small to moderate lesions | Freezing-induced necrosis | 60–80% | | Surgical excision/LEEP | Large, resistant, or suspicious lesions | Mechanical removal | >90% | | Imiquimod + surgical | Extensive disease | Combined approach | Optimal | **High-Yield:** In this immunocompetent woman with benign HPV types and no alarming features, **topical imiquimod** is first-line. It is non-invasive, can be self-applied, and activates local immune response to clear the virus. **Clinical Pearl:** Condyloma acuminata caused by HPV-6/11 have excellent prognosis. Spontaneous regression occurs in 20–30% of cases over 3–5 years, but active treatment accelerates clearance and reduces transmission. ### Why LEEP is NOT First-Line Here - LEEP is reserved for: - Large, resistant lesions unresponsive to topical therapy - Lesions with atypical cytology or suspicion of malignancy - Intra-anal or high-grade lesions - In this case, the lesions are benign (HPV-6/11), accessible, and of moderate extent — topical therapy is appropriate first. **Mnemonic: WART** — **W**arts from low-risk HPV → **A**void aggressive surgery → **R**espond well to **T**opical immunotherapy.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.